SCH 56592

Phase 2Small molecule

Merck & Co.

SCH 56592 is one of 358 small molecule programs targeting Lung Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

357

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung CancerActive, not recruiting

ParkinsonismActive, not recruiting

Chronic HepatitisActive, not recruiting

Chronic Obstructive Pulmonary DiseaseActive, not recruiting

Alcohol DependenceActive, not recruiting

Acute Lymphoblastic LeukemiaActive, not recruiting

Chronic Lymphocytic LeukemiaActive, not recruiting

HypercholesterolemiaActive, not recruiting

AsthmaActive, not recruiting

Chronic CoughActive, not recruiting

Lung CancerPhase 2

Active, not recruiting

ParkinsonismPhase 1

Active, not recruiting

Chronic HepatitisPhase 2

Active, not recruiting

Chronic Obstructive Pulmonary DiseasePhase 1

Active, not recruiting

Alcohol DependencePhase 2

Active, not recruiting

Acute Lymphoblastic LeukemiaPhase 2

Active, not recruiting

Chronic Lymphocytic LeukemiaPhase 2

Active, not recruiting

HypercholesterolemiaPhase 2

Active, not recruiting

AsthmaPhase 2

Active, not recruiting

Chronic CoughPhase 2

Active, not recruiting

Showing 10 of 12 indications

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

Veramyst

GSK

Preclinical

46 2

Xolair

Roche

Preclinical

25 3

Singulair

AstraZeneca

Preclinical

17 4

SCH 56592

Merck & Co.

Phase 2

1 5

Nucala

GGlaxo Dba Glaxosmithkline

Preclinical

35 6

Formoterol Fumarate

AstraZeneca

Preclinical

8 7

Symbicort

AstraZeneca

Preclinical

6 8

Aciphex

Akero Therapeutics

Preclinical

2 9

Atrovent

Boehringer Ingelheim

Preclinical

2 10

Decadron

QQuince Therapeutics S.p.A.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Advanced Cancer2 trials

Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT00871663·123 enrolled

Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT00871910·81 enrolled

Chronic Cough2 trials

Study of the Efficacy and Safety of SCH 619734 in Subjects With Chronic Cough From an Unknown Cause (Study P04888)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00506545·35 enrolled

Study of the Efficacy and Safety of SCH 486757 in Subjects With Chronic Cough (Study P04887)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00506987·31 enrolled

Efficacy and Safety1 trial

A Study to Evaluate Efficacy and Safety of Four Posaconazole Regimens With Placebo and Terbinafine in the Treatment of Toenail Onychomycosis (Study P05082AM2)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00491764·218 enrolled

Alcohol Dependence1 trial

Trial Investigating the Efficacy and Safety of SCH 900435 (Org 25935) in Relapse Prevention in Participants With Alcohol Dependence (P05718)

Terminated· Merck & Co. logo

Merck & Co.·Phase 2·NCT00764660·141 enrolled

Asthma1 trial

Study of SCH 527123 in Subjects With Severe Asthma (Study P05109AM1)

Withdrawn· Merck & Co. logo

Merck & Co.·Phase 2·NCT01006161

17 more indications

Percutaneous Coronary Intervention1 trial

Safety of SCH 530348 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention (Study P03573)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00132912·1,030 enrolled

Drug1 trial

A Follow up Safety Study of Patients Who Participated in Previous Studies of the Drug Org 24448 (Study P05719)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.··NCT00780585·95 enrolled

Chronic Obstructive Pulmonary Disease1 trial

Two-Part Study to Evaluate the Dose Response of SCH 527123 on Sputum Neutrophilia Following Ozone Challenge in Healthy Subjects and Chronic Obstructive Pulmonary Disease (COPD) Patients (P05567 AM7)

Terminated· Merck & Co. logo

Merck & Co.·Phase 1·NCT01068145·18 enrolled

Overweight1 trial

Efficacy and Safety Trial to Evaluate the Effect of SCH 497079 on Weight in Obese and Overweight Participants (Study P05483)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00642993·401 enrolled

TED1 trial

Effect of SCH 497079 on Metabolic Parameters and Influence of Race/Ethnic Origin on Therapeutic Response (Study P05338)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT00673465·17 enrolled

Trial1 trial

Safety of Org 34517 900 mg in Patients Who Received Org 34517 in a Previous Trial (Study 28133/P05842)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00844922·16 enrolled

Acute Lymphoblastic Leukemia1 trial

SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED)

Terminated· Merck & Co. logo

Merck & Co.·Phase 2·NCT00798213·29 enrolled

Cough1 trial

Comparison of SCH 486757 to Codeine and Placebo in Subjects With Persistent Postviral Cough (Study P03069AM2)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00230230·91 enrolled

Parkinsonism1 trial

Acute Effects of Preladenant (SCH 420814) on Dyskinesia and Parkinsonism in Levodopa Treated Participants (P05550)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT00845000·12 enrolled

Chronic Hepatitis1 trial

A Pharmacokinetics/Pharmacodynamics Study of SCH 900518 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C (Protocol No. P05104AM2)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00797745·111 enrolled

Chronic Lymphocytic Leukemia1 trial

SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715)

Terminated· Merck & Co. logo

Merck & Co.·Phase 2·NCT00871546·8 enrolled

Hypercholesterolemia1 trial

Phase 2 Dose-Ranging Efficacy and Safety Trial of SCH 900271 in Participants With Primary Hypercholesterolemia or Mixed Hyperlipidemia (P05675)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00941603·619 enrolled

Lung Cancer1 trial

SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00732810·97 enrolled

Seasonal Allergic Rhinitis1 trial

Study of the Effect of SCH 900538 on Congestion in Subjects With Seasonal Allergic Rhinitis (Study P05031)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00673062·265 enrolled

Schizophrenia1 trial

Efficacy & Safety of SCH 900435 in Schizophrenia (Study P06079)(WITHDRAWN)

Withdrawn· Merck & Co. logo

Merck & Co.·Phase 2·NCT00988728

Parkinson's Disease1 trial

Single Dose Study to Assess the Pharmacokinetics of SCH 900800 in Subjects With Parkinson's Disease Being Treated With Levodopa (L-DOPA) (P08235)

Withdrawn· Merck & Co. logo

Merck & Co.·Phase 1·NCT01500707

Unspecified1 trial

A Bioequivalence Study of SCH 530348 2.5 mg Tablets (P06558)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT01358344·173 enrolled

Sources

References

[1]
ClinicalTrials.gov — 24 trial records for SCH 56592. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SCH 56592 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SCH 56592. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Merck & Co.

SCH 56592

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Advanced Cancer2 trials

Chronic Cough2 trials

Efficacy and Safety1 trial

Alcohol Dependence1 trial

Asthma1 trial

Percutaneous Coronary Intervention1 trial

Drug1 trial

Chronic Obstructive Pulmonary Disease1 trial

Overweight1 trial

TED1 trial

Trial1 trial

Acute Lymphoblastic Leukemia1 trial

Cough1 trial

Parkinsonism1 trial

Chronic Hepatitis1 trial

Chronic Lymphocytic Leukemia1 trial

Hypercholesterolemia1 trial

Lung Cancer1 trial

Seasonal Allergic Rhinitis1 trial

Schizophrenia1 trial

Parkinson's Disease1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News